FDA Greenlights Insys Therapeutics’ Syndros

The FDA has approved Insys Therapeutics’ Syndros, an oral cannabinoid dronabinol that is designed to treat anorexia-linked weight loss in AIDS patients.

Additionally, the oral solution was approved to treat nausea and vomiting associated with chemotherapy in patients when traditional antiemetic treatments are not sufficient.

The drug still requires DEA approval before going to market.